...
首页> 外文期刊>Journal of Pharmaceutical and Biomedical Analysis: An International Journal on All Drug-Related Topics in Pharmaceutical, Biomedical and Clinical Analysis >Plasma protein binding, pharmacokinetics, tissue distribution and CYP450 biotransformation studies of fidarestat by ultra high performance liquid chromatography-high resolution mass spectrometry
【24h】

Plasma protein binding, pharmacokinetics, tissue distribution and CYP450 biotransformation studies of fidarestat by ultra high performance liquid chromatography-high resolution mass spectrometry

机译:非达司他血浆蛋白的结合,药代动力学,组织分布和CYP450生物转化的超高效液相色谱-高分辨率质谱研究

获取原文
获取原文并翻译 | 示例

摘要

Fidarestat, an aldose reductase inhibitor, has been used for the treatment of the diabetic associated complications such as retinopathy, neuropathy and nephropathy. To better understand the metabolism and pharmacokinetics of fidarestat, we have evaluated plasma protein binding, pharmacokinetics, tissue distribution of the drug and its conjugated metabolites and CYP450 biotransformation by liquid chromatography-high resolution mass spectrometry. Effective chromatographic separation of fidarestat and hydrochlorothiazide (IS) in rat plasma and tissues was achieved on Hypersil gold C-18 column in an isocratic elution mode. For detection, a high-resolution Orbitrap mass spectrometer with heated electrospray ionization inlet in the negative ion mode was used. High-resolution extracted ion chromatograms for each analyte were obtained by processing the full-scan MS mode with 5 ppm mass tolerance. The impact of plasma protein binding with the drug and conjugated metabolites of the drug on pharmacokinetics has been determined. The study indicated that 9.5% of free form of fidarestat may be pharmacologically active and the C-max for free fidarestat was found to be 80.30 +/- 6.78 ng/mL. The AUC(0-t) and AUC(0-infinity) were found to be 185.46 +/- 32 and 195.92 +/- 15.06 ng h/mL, respectively. Among tissues, the maximum observed distribution was found to be in kidney followed by liver and heart. Docking experiments and in vitro CYP450 reaction phenotyping revealed that two CYP1A2 and CYP2D6 are involved in the phase I metabolism of fidarestat. Oxidative deamination and N/O glucuronidation are the major phase land phase II metabolites, respectively. In vitro CYP450 inhibition assay of fidarestat for drug-drug interaction showed weak inhibition and may not alter pharmacokinetics, distribution or clearance of other co-administered drug. (C) 2014 Elsevier B.V. All rights reserved.
机译:醛糖还原酶抑制剂非达司他已用于治疗糖尿病相关并发症,如视网膜病变,神经病变和肾病。为了更好地了解非达司他的代谢和药代动力学,我们通过液相色谱-高分辨率质谱法评估了血浆蛋白结合,药代动力学,药物及其共轭代谢产物的组织分布以及CYP450的生物转化。在Hypersil gold C-18色谱柱上以等度洗脱模式实现了大鼠血浆和组织中非来司他和氢氯噻嗪(IS)的有效色谱分离。为了进行检测,使用了高分辨率的Orbitrap质谱仪,该质谱仪在负离子模式下具有加热的电喷雾电离入口。通过以5 ppm的质量公差处理全扫描MS模式,可获得每种分析物的高分辨率提取离子色谱图。已经确定血浆蛋白与药物的结合以及该药物的共轭代谢产物对药代动力学的影响。研究表明,非达拉司他游离形式的9.5%具有药理活性,游离非达司他的C-max为80.30 +/- 6.78 ng / mL。发现AUC(0-t)和AUC(0-无穷大)分别为185.46 +/- 32和195.92 +/- 15.06 ng h / mL。在组织中,观察到的最大分布是在肾脏中,其次是肝脏和心脏。对接实验和体外CYP450反应表型显示,两个CYP1A2和CYP2D6参与非达司他的I期代谢。氧化脱氨和N / O葡萄糖醛酸化分别是陆相II相的主要代谢产物。非达司他的体外CYP450抑制试验对药物相互作用的抑制作用较弱,可能不会改变其他共同给药药物的药代动力学,分布或清除率。 (C)2014 Elsevier B.V.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号